Anti-Mouse CD22 [Clone MB22-11] — Purified in vivo GOLD™ Functional Grade
Anti-Mouse CD22 [Clone MB22-11] — Purified in vivo GOLD™ Functional Grade
Product No.: C960
Clone MB22-11 Target CD22 Formats AvailableView All Product Type Hybridoma Monoclonal Antibody Alternate Names Lyb-8, Siglec-2, BL-CAM Isotype Mouse IgG2c κ Applications ELISA , FA |
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Mouse Recommended Dilution Buffer Immunogen Mouse CD22 cDNA-transfected baby hamster kidney cells Product Concentration ≥ 5.0 mg/ml Endotoxin Level ≤ 1.0 EU/mg as determined by the LAL method Purity ≥95% by SDS Page ⋅ ≥95% monomer by analytical SEC Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. State of Matter Liquid Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Regulatory Status Research Use Only Country of Origin USA Shipping 2-8°C Wet Ice Additional Applications Reported In Literature ? ELISA, FA Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity MB22-11 activity is directed against mouse CD22 (Siglec-2). Background Siglecs (sialic acid-binding immunoglobulin superfamily lectins) are a family of single pass, transmembrane cell surface proteins characterized by shared structural motifs and an ability to recognize sialic acids1, 2. CD22 (Siglec-2), a 140 kDa member of the Siglec family expressed by B cells3, 4, contains six C2-set domains, one V-set domain, and in its intracellular cytoplasmic tail has three immunoreceptor tyrosine-based inhibition motifs (ITIM) and one ITIM-like domain5. While murine Siglecs are not necessarily homologous to human Siglecs, CD22 is evolutionarily conserved and does have a direct human ortholog5. CD22 acts as an inhibitory B cell co-receptor that negatively regulates B cell activation, B reg cell expansion, and B cell receptor (BCR) signaling4. Upon ligation of BCR, ITIMs are phosphorylated, leading to recruitment and activation of SH2-containing phosphatases that then dephosphorylate signaling molecules activated by BCR ligation4. Additionally, CD22 regulates B cell response to inflammation and is a master regulator of microglial phagocytosis in the aging brain5. Evidence in mouse models suggests CD22 contributes to the pathogenesis of autoimmune diseases3. Loss of CD22 leads to hyperactivation of B cells5. CD22 mouse knockouts are defective in B cell development but do not develop lupus-like disease4. To generate MB22-11, CD22 knockout mice were immunized with mouse CD22 cDNA-transfected baby hamster kidney cells6. Spleen cells were fused with NS-1 myeloma cells, and hybridomas producing antibody specifically reactive with CD22-transfected mouse L cells were selected and purified. MB22-11 was isotyped as IgG2c due to its C57BL/6 origin; however, both IgG2a and IgG2c specific reagents have significant reactivity against MB22-11. In vitro, MB22-11 inhibits CD22-mediated adhesion by 90% and completely blocks CD22-Fc binding to T and B cells6. In vivo, MB22-11 significantly reduces peripheral blood, lymph node, and marginal zone B cell numbers6, 7. Additionally, in mice injected with MB22-11, blood, spleen, and lymph node B cell turnover is higher relative to injection with non-blocking monoclonal antibodies, and B cell surface expression of CD22 is reduced to nearly undetectable levels6. Antigen Distribution CD22 is expressed by most mature B cell lineages. Ligand/Receptor SHP-1, Syk, Lck, and Lyn NCBI Gene Bank ID UniProt.org Research Area Cell Adhesion . Immunology Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Common In Vivo Applications of Clone MB22-11 in Mice Clone MB22-11 is a mouse anti-mouse CD22 monoclonal antibody used extensively in in vivo mouse studies. Here are some of its common applications:
Commonly Used Antibodies and Proteins with MB22-11MB22-11 is a widely used monoclonal antibody specific to mouse CD22, often employed to study B cell biology and signaling. Several related antibodies and proteins are commonly used alongside MB22-11 in the literature, either as controls, detection reagents, or for functional studies. Common Companion Antibodies
Functional and Signaling Proteins
Experimental Contexts
Summary Table
Key Points
These combinations allow researchers to rigorously analyze CD22 function, B cell biology, and the mechanisms of MB22-11 action in both in vitro and in vivo settings. Key findings from scientific literature citing clone MB22-11 (an anti-mouse CD22 monoclonal antibody) are:
In summary, MB22-11 is chiefly cited as a valuable reagent for robust, specific, and rapid in vivo depletion of mature B cells in mouse models, allowing researchers to dissect B cell roles in immunity and disease through CD22 blockade or depletion protocols. Dosing regimens of clone MB22-11 (anti-mouse CD22 monoclonal antibody) are generally consistent across different mouse models, such as NZB/W F1 and C57BL/6, with typical doses around 100 μg per mouse administered to achieve B cell depletion. However, minor adjustments can be made depending on experimental objectives or to tailor the duration and extent of B cell depletion. Key details:
In summary, MB22-11 dosing typically does not require major adjustment based on mouse strain; instead, any variations are driven by the specific goals of the experiment. References & Citations1. Bochner BS. Clin Exp Allergy. 39(3):317-324. 2009. 2. Kiwamoto T, Kawasaki N, Paulson JC, et al. Pharmacol Ther. 135(3):327-336. 2012. 3. Dörner T, Shock A, Smith KG. Int Rev Immunol. 31(5):363-378. 2012. 4. Tsubata T. Immunol Med. 42(3):108-116. 2019. 5. Siddiqui SS, Matar R, Merheb M, et al. Cells. 8(10):1125. 2019. 6. Haas KM, Sen S, Sanford IG, et al. J Immunol. 177(5):3063-3073. 2006. 7. Haas KM, Watanabe R, Matsushita T, et al. J Immunol. 184(9):4789-4800. 2010. Technical Protocols FA Certificate of Analysis |
Formats Available
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
